FIGURE 3 | Sites of action of therapeutic compounds that modulate gene transcription.
From the following article:
Experimental therapeutics in transgenic mouse models of Huntington's disease
M. Flint Beal & Robert J. Ferrante
Nature Reviews Neuroscience 5, 373-384 (May 2004)
doi:10.1038/nrn1386
Histone deacetylase (HDAC) inhibitors and mithramycin modulate the binding of transcription factors, which then alters gene transcription to counteract the effects of mutant huntingtin (Htt) on transcription. CBP, CREB (cyclic-AMP-response element-binding protein) binding protein; HD, Huntington's disease.
Download file
If the slide opens in your browser, select "File > Save As" to save it.
